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Localization of transforming growth factor-j3 and latent transforming
growth factor-a binding protein in rat kidney. TGF-p plays an important
role in maintaining the renal histological structure, and glomerular and
tubular function. TGF-13 is usually secreted in a biologically inactive or
latent form with high molecular weight by normal cells. The latent form
of TGF-/3 is composed of three distinct components: (a) mature TGF-J3
(b) TGF-13 latency associated peptide (LAP) (c) latent TGF-/3 binding
protein (LTBP). LTBP plays a central role in the assembly, secretion and
activation of TGF-131. Most cells secrete a large latent TGF-/3 with LTBP,
while the other cells secrete a small latent TGF-p without LTBP.
However, the precise localization of TGF-13 and LTBP in the kidney is still
not known. In the present study, we used the reverse transcription in
combination with polymerase chain reaction (RT-PCR) to investigate the
precise localization of TGF-131 and LTBP in the microdissected glomeruli,
renal tubules and arterioles. Our findings showed that TGF-J31 mRNA
was detected in all nephron segments, glomeruli, and arterioles. On the
other hand, LTBP mRNA was present in the glomeruli and arterioles,
while it was absent in every segment of the renal tubules. Moreover, the
immunohistochemical study of LTBP showed that the LTBP protein was
localized on the glomeruli and arterioles but not on the renal tubules at
the same localization as LTBP mRNA. These results indicate that the
tubular epithelial cells secrete the small latent TGF-pl, while glomerular
cells secrete the large latent TGF-$31, suggesting that they both have
different structures and thus potentially different biological functions.
Transforming growth factor-13 (TGF-p) has a potent effect on
the proliferation and differentiation of a variety of cell types as
well as a combined effect in enhancing the synthesis of the
extracellular matrix (ECM). TGF-13 has been shown to play an
important role in maintaining the renal histological structure as
well as the glomerular and tubular function. Our previous studies
have demonstrated a close association between the elevated
expression of TGF-p and the development of glomerulonephritis
[1], glomerulosclerosis or interstitial fibrosis [2], and the suppres-
sion of experimental disease achieved with the anti-TGF-/3 anti-
body [3]. The effects of TGF-/3 on tubulogenesis [4] tubular cell
hypertrophy [5] and tubular functions such as phosphate transport
[61 have also been shown in recent studies. Thus, TGF-f31 has a
unique structure and several kinds of receptors that may make this
growth factor biologically mutifunctional.
TGF-131 is usually secreted by normal cells in a biologically
inactive or latent form with high molecular weight [7—9]. The
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latent form of TGF-131 is composed of three distinct components
(Fig. 1): (a) mature TGF-31, that is, biologically active; (b) the
TGF-pl latency associated peptide (LAP), that is, sufficient for
TGF-13 latency; and (c) the latent TGF-f31 binding protein
(LTBP) [10, 11]. LAP is linked to a single molecule of LTBP by a
disulphide bond. A recent report stated that LTBP plays a central
role in the assembly, secretion and activation of TGF-pl. How-
ever, LTBP and TGF-f3 are not always co-expressed. Most cells
secrete a large latent TGF with LTBP, while the other cells
secrete a small latent TGF-/3 without LTBP [10—14]. Our previous
study of progressive renal deterioration model also showed a
discrepancy between LTBP message and TGF-f31 message in the
diseased kidney [2].
The kidney is a heterogeneous organ, and thus information on
the precise localization of TGF-f31 and LTBP mRNA expression
is necessary to understand the renal action of TGF-f31. In the
present study, we used reverse transcription in combination with
polymerase chain reaction (RT-PCR) to investigate the precise
localization and regulation of TGF-131 and LTBP in micro-
dissected glomeruli, renal tubules and arterioles.
Methods
Experimental animals and microdissection
Male Sprague-Dawley rats weighting 80 to 100 g were obtained
from Seiwa Experimental Animal Ltd. (Fukuoka, Japan). After
administering anesthesia, the kidneys were perfused via the aorta
with ice-cold microdissection solution (Hanks' balanced solution
(Nissui, Tokyo Japan), pH 7.4 containing 10 mt Hepes and
1 mg'ml collagenase (Worthington Biochemical, Freehold, NJ,
USA). Next the kidneys were removed, and thin coronal slices
were made and then kept in ice-cold microdissection solution
containing 10mM vanadyl ribonucleotide complex (BRL, Gaithers-
burg, MD, USA). The segments were microdissected under a
stereomicroscope using fine forceps. The tubule segments were
identified according to the established criteria [15, 16]. We
microdissected the following structures: glomerulus (Glm), prox-
imal convoluted tubule (PCT), proximal straight tubule (PST),
medullary ascending limb of Henle (MAL), cortical ascending
limb of Henle (CAL), distal convoluted tubule (DCT), cortical
collecting duct (CCD), inner medullary collecting duct (IMCD)
and afferent or efferent arterioles. The length of the tubules
ranged between 1.5 to 2.0 mm. The microdissected samples were
rinsed, quickly frozen and kept in —80°C until RNA extraction.
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Fig. 1. Schematic representation of the (A) small
latent TGF-/31 comples and the (B) large latent
TGF-131 complex. The small latent TGF-pl
complex is composed of the mature TGF-j31
dimer and a dimer of the N-terminal remnant
of the TGF-131 precursor, which is denoted
TGF-(31 latency associated peptide (TGF-pl
LAP). TGF-/31 LAP is noncovalently associated
with the mature TGF-J31. The large latent
x 2) TGF-pl complex consists of the third
component, which is denoted the latent TGF-13
binding protein (LTBP), and the small latent
TGF-j31 complex. LTBP binds to TGF-/31 LAP
by a disuiphide bond. (adapted from
Miyazonon K, Ichijo H, and Heldin CH [9];
used with permission).
Preparation of RNA
RNA was extracted from the microdissected tissues by the
single-step acid guanidinium thiocyanate-phenol-chioroform ex-
traction method [17] using Isogen (Nippon Gene, Tokyo, Japan)
and ethachinmate (Nippon Gene) as a carrier for microextraction.
Reverse transcription
Reverse transcription (RT) was performed using the GeneAmp
RNA PCR kit (Perkin-Elmer Cetus, Norwalk, CT, USA). First-
strand cDNA was synthesized from RNA by Moloney murine
leukemia virus reverse transcriptase following the instructions of
the manufacturer, with 2.5
.LM of random hexamers in a total
volume of 20 p1. The reaction buffer consisted of 10 m'vi Tris-HC1
(pH 8.3), 50 mrvi KC1, 5 mt MgCI2, 1 U RNase inhibitor and 1 mM
dNTP. The reaction tubes were incubated at 23°C for 15 minutes,
42°C for 45 minutes, 99°C for 5 minutes in the program temper-
ature control system PC-700 (Astec, Fukuoka, Japan) and then
were placed on ice until PCR.
Primer and oligonucleotide design
For the rat TGF-pl gene, the sense primer was 5'-GGACTAC-
TACGCCAAAGAAG-3' defined by bases 715-734, the antisense
primer was 5'-TCAAAAGACAGCCACTCAGG-3' defined by
bases 989-1008, according to full-length rat TGF-pl cDNA [18].
For the rat LTBP gene, the sense primer was 5'-GTGTATC-
CCGTGGCTGCTAA-3' defined by bases 1948-1967, the anti-
sense primer was 5'-ATCTGCTTGGTGAGGTGAAC-3' defined
by bases 2392-2411 according to full-length rat LTBP cDNA [10].
For the rat glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
gene as a positive control, the sense primer was 5'-TCCCTCAA-
GATTGTCAGCAA-3', and the antisense primer was 5'-AG-
ATCCACAACGGATACATT-3' [19]. The amplification specific
oligonucleotide (antisense) probes for Southern blotting were as
follows: TGF-131, 5'-GCACGGGACAGCAATGGGGG-3'; LTBP,
5' -AAGCCCCAGGAGGTCCCCAC-3'; GAPDH, 5 '-GGAT-
GACCTTGCCCACAGCC-3'. The primers and oligonucleotides
were synthesized at either the Takara Shuzo Co. (Kyoto, Japan)
or Bio-Synthesis (Lewisville, TX, USA).
Polymerase chain reaction
We amplified the synthesized first-strand cDNA by polymerase
chain reaction (PCR) with 40 pmol of each primer in a total
volume of 100 p1. The reaction buffer consisted of 10 mrvi Tris-HC1
(pH 8.3), 50 mtvi KC1, 2 mtt MgC12, 200 LM dNTP and 2.5 U
AmpliTaq DNA polymerase (Perkin Elmer Cetus). The PCR
reactions were performed in a program temp control system
PC-700, with an initial denaturation step at 94°C for five minutes,
and then were cycled 40 times for one minute at 94°C, followed by
one minute at 55°C and two minutes at 72°C. Then the reaction
tubes were maintained at 72°C for an additional seven minutes
before completion. An 8 p1 aliquot of PCR products was electro-
phoresed on 1.8% agarose gel. After staining by ethidium bro-
mide, DNA bands were visualized with an ultraviolet transillumi-
nator. For the DNA size marker, 100 bp DNA ladder (BRL) was
used. Throughout the experiment, false-positive PCR results were
avoided by the strict application of the contamination prevention
measures [20].
Southern blotting
For the Southern blot analysis, the gels were denatured,
neutralized, and blotted onto a nylon membrane Nytran (Schlei-
cher & Schuell, Dassel, Germany). The synthesized oligonucleo-
tide probes were 5' end-labeled with [y-32P]ATP using ready-
to-go T4 polynucleotide kinase (Pharmacia P-L Biochemicals,
Milwaukee, WI, USA). After hybridization for 18 hours at 50°C in
1% SDS, 6x SSC, 10% dextran sulphate and 100 mg/mI heat-
denatured salmon sperm DNA, the filters were washed in 2xSSC
and in 2xSSC and 1% SDS. Autoradiography was performed by
the standard method.
Immunohistochemical study
To examine the distribution of LTBP, an indirect immuno-
fluorescence study was performed. The primary antibody used
was rabbit polyclonal anti-LTBP antibody Ab39, provided by
Dr. Miyazono (Ludwig Institute for Cancer Research, Uppsala,
Sweden) [8]. The frozen tissue specimens were sectioned at a
thickness of 4 sm using a cryostat. Air-dried sections were fixed in
cold acetone, incubated for 24 hours with the first antibody, and
then reacted overnight with fluoresceinisothiocyanate (FITC)-
labeled goat anti-rabbit IgG (Organon Teknika Corp., West
Chester, PA, USA) in a humidified chamber at 4°C. As a negative
control, anti-LTBP antibody was preabsorbed with native LTBP
before carrying out the immunohistochemical study [21].
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Results
Specificily of the oligonucleotide primers and the effect of reverse
transcnption on TGF-f31, LTBP, and GAPDH mRI'JA
amplification
As shown in Figure 2, we could detect a clear single band of
TGF-pl, LTBP, and GAPDH from rat kidney RNA by RT-PCR.
Each PCR product was the predicted size, 294 bp for TGF-/31, 464
bp for LTBP, and 308 bp for GAPDFI, on the ethidium-bromide
stained agarose gel. Figure 2 also showed that when the RT-PCR
procedure was carried out without reverse transcriptase, there was
no recognized band on agarose gel. These results indicated that
these bands originated from mRNA, not from genomic DNA.
Distribution of TGF-pl mRNA in microdissected structures
As shown in Figure 3A, the specific mRNA of TGF-/31 could be
detected from glomeruli, all components of renal tubules (PCT,
PST, MAL, CAL, DCT, CCD, IMCD) and arterioles in the rat
kidney by gel electrophoresis. The Southern blot analysis of the
gel demonstrated specific binding of the oligonucleotide probe to
the 294 bp product (Fig. 3B). The amplification product of
GAPDH was detected from all renal segments at a predicted size
308 bp and served as a positive control for the RT-PCR reaction.
Distribution of LTBP mRNA in microdissected structures
In contrast to TGF-/31 mRNA, LTBP mRNA was only detected
in the glomerulus and arteriole, but not in any components of the
tubular segments by gel electrophoresis (Fig. 3A). The Southern
blot analysis of the gel showed the specific binding of the
oligonucleotide probe to the 464 bp product of glomerulus and
arteriole, but no detectable signals were observed from any
components of the tubular segments (Fig. 3B).
Distribution of LTBP by immunohistochemical study
To confirm the heterogeneity of LTBP localization in the
kidney, we performed an immunohistochemical study. The immu-
nostaining of anti-LTBP antibody Ab 39 was detected in the
glomeruli and the arterioles but not in the renal tubules (Fig. 4).
Fig. 2. The specificity of PCR primers and the effect of
reverse transcription on TGF-131, LTBP, and GAPDH
mRNA amplification. RT-PCR was performed from
rat kidney RNA with oligonucleotide primers for
TGF-131, LTBP, and GAPDH. The assay was carried
out in either the presence (+) or absence (—) of
reverse transcriptase. The left lane shows the
molecular weight marker [100 bp DNA ladder
(BRL)].
In the glomeruli, LTBP was present in the mesangial area and
along the capillary wall. The immunostaining was blocked by a
preabsorption of anti-LTBP antibody (Ab 39) with LTBP (data
not shown).
Discussion
TGF-131 has been focused on as a main factor in regulating
glomerular sclerosis and interstitial fibrosis because of its wide-
spread effects on ECMs. TGF-31 actions on ECMs are mediated
through regulatory effects on ECM synthesis [22—24], enzymes
that degrade ECM [25, 261, and the expression of ECM receptor
on cells [27]. In fact, TGF-pl also has a dramatic effect on the
production of ECM in the cultured rat glomerular mesangial cells
[28]. Our previous study showed that an experimental model of
glomerulonephritis, anti-Thy-i nephritis in the rats, was associ-
ated with an increased production and activity of TGF-f31 [1]. The
suppression of the experimental disease achieved with anti-
TGF-13i antibody treatment indicates the importance of TGF-pl
in regulating ECM production [3]. In the progressive glomerulo-
sclerosis model, the progressive increase in the expression of
TGF-J31 was also revealed in the process of glomerulosclerosis
and interstitial fibrosis [2].
In addition to the role in histopathological changes, the effect of
TGF-/31 on tubulogenesis was shown by a recent study in which
the combined addition of TGF-f3i with epidermal growth factor
(EGF) and retinoic acid induced rabbit proximal tubular cells
in the monolayer to transform into cell aggregates containing
lumens [4]. TGF-f3i selectively inhibits the activity of the sodium-
dependent Pi transport system present in the apical membrane of
epithelial cells through the pathway that might involve a serine/
threonine protein kinase [6]. Water deprivation was also reported
to stimulate TGF-13 accumulation in the juxtaglomerular appara-
tus of the mouse kidney [29]. Recent observations raised the
possibility that TGF-p may mediate the hypertrophic effect of
angiotensin II on tubular epithelial cells [5]. Since the kidney is a
heterogeneous organ, it is important to know which nephron
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Fig. 3. The detection of TGF-131, LTBP, and
GAPDH in microdissected renal segments by RT-
PCR. A. Ethidium-bromide-stained agarose gel
for TGF-j31, LTBP, and GAPDH. The arrows
indicate predicted PCR product size: TGF-pl
(294 bp), LTBP (464 bp), and GAPDH (308 bp).
The abbreviations for the microdissected renal
segments are: glomeruli (Gm), proximal
convoluted tubule (PCT), proximal straight
tubule (PST), medullary ascending limb of Henle
(MAL), cortical ascending limb of Henle (CAL),
distal convoluted tubule (DCT), cortical collecting
duct (CCD), inner medullary collecting duct
(IMCD) and arterioles (art). The left lane shows
the molecular weight marker (100 bp DNA ladder).
B. The autoradiograms of the corresponding
Southerm blots. The blots were hybridized with a
32P-labeled oligonucleotide probe localized
between the sense and antisense PCR primers for
TGF-f31, LTBP, or GAPDH.
segment expresses the TGF-j3 components in order to understand
the multifunctions of TGF-p on renal cells.
In the adult rat kidney there are high levels of TGF-131 mRNA
and protein in the glomeruli [30]. By immunohistochemistry, the
greatest staining of the TGF-/31 protein is observed in the tubular
epithelial cells [31]. Recently, by using antibody against each of
isoforms, it has been found that TGF-/31 and TGF-f33 are present
in the tubular cells, whereas TGF-132 staining is faint in the
glomerulus and tubules [29]. In our previous study, a part of
tubular epithelial cells and infiltrating cells in diseased kidney
tissues was stained with anti-LC antibody, which is considered to
react with TGF-pl producing cells [2]. In situ hybridization
experiments also showed increased TGF-/31 mRNA in glomerular
and tubular cells (unpublished data). In the present study,
TGF-pl mRNA expression in every segment of nephron con-
firmed that every nephron segment has the ability to produce
TGF-pl.
In contrast to TGF-131 mRNA, LTBP mRNA was only ex-
pressed in glomerulus and arteriole but not in the tubular
segments. In rat tissue, there is usually a good correlation between
LTBP mRNA and TGF-f31 mRNA in a variety of different tissues
[101. However, the LTBP and TGF-/3 precursors are not always
co-expressed. For example, the thymus does not express LTBP
[10]. The organ cultures of normal bone produce the 100 kDa
(small) form of latent TGF-13 [32]. In scirrhous gastric carcinoma
tissue, mesenchymal cells produce and secrete both LTBP and
TGF-J31, whereas cancer cells produce TGF-131, which is mainly
observed in the cytosol [33]. LTBP is lacking in malignant
prostatic tissue but not in benign prostatic tissue [13]. This
discrepancy between TGF-f31 mRNA and LTBP mRNA was also
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Fig. 4. Immunofluorescent microscopy of the rat kidney for LTBP. Renal section of a thickness of 4 m was stained with anti-LTBP antibody Ab39
followed by FITC-conjugated second antibody. Immunoreactivity for LTBP is located in the glomerulus and the arteriole but not in the renal tubules.
Original magnification, X 200.
observed in the advanced renal deterioration in our previous study
[2]. Thus latent TGF-p complex synthesized by various cells may
have two different structures of small latent TGF-f31 (mature
TGF-f31 + LAP) and large latent TGF-f31 (mature TGF-pl +
LAP + LTBP), and thus potentially have different biological
functions in vivo.
It has also been demonstrated that LTBP participates in the
activation of the latent TGF-/31 complex probably due to concen-
trating the latent growth factor on the cell surface where activa-
tion occurs [3I. The direct interaction of the latent TGF-/3
complex and cell-surface molecule is necessary for the activation
of the latent complex [35]. The LTBP molecule has two different
types of cystine-rich repeat sequences: epidermal growth factor
(EGF)-like repeats and the eight-cystine repeats [10, 11]. The
functions of EGF-like motifs are still not fully understood, but
they may play important roles in both homophilic and/or hetero-
philic protein-protein interactions [361. Epidermal growth factor
(EGF)-like domains and the internal repeats with eight cystines in
LTBP may act as a functional domain to release mature TGF-f31
from the latent complex by interaction with the cell surface or
matrix macromolecules [10] [341. It is interesting that the extra-
cellular matrix protein fibrillin was recently found to be remark-
ably similar to LTBP with several EUF-like repeats and the novel
eight-cystine repeat [37]. There has also been a recent report in
which LTBP plays a critical role in the assembly and secretion of
latent TGF-j31 complex [38]. The TGF-131 precursor remains
inside the cells in an unprocessed form for a longer time period
and small latent TGF-pl without LTBP is secreted very slowly. In
contrast, the large latent TGF-131 complex is secreted rapidly after
the synthesis of LTBP.
The present study suggested that tubular epithelial cells secrete
the small latent TGF-f3 complex, while the glomerular and
vascular cells secrete the large latent TGF-p complex in the
normal rat kidney. The functional differences between the small
latent TGF-/3 and large latent TGF-/3 are still not clear; however,
it may be related to the effects of LTBP on the interaction of
latent TGF-/3 with matrix component, the regulation of TGF-f3
activation or the promotion of TGF-13 secretion. LTBP plays an
important role in targeting the latent TGF-f3 complexes to a
specific localization [34, 39]. This may result in a difference in the
tissue distribution, and the possible efficiency of activation, be-
tween the large and small latent TGF-13 complexes. In a recent
report of bone cells, Dallas et al speculated that the large latent
TGF-f3 complex may represent a matrix storage form of TGF-13,
while the small latent TGF-f3 complex may represent a secretory
form, providing a pool of latent TGF-f3 that is more readily
available to the cell for activation [40]. Immunohistological stud-
ies have revealed that LTBP is often localized in connective
tissues [13, 33]. The large latent TGF-j3 complex associates with
the extracellular matrix rapidly after secretion [39]. Therefore, it
is likely that the large latent TGF-13 produced by glomerular or
vascular cells might control the intraglomerular matrix or vascular
basement membrane matrix by interaction with the matrix com-
ponent.
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In contrast, the small latent TGF-f3 complex which is slowly
secreted by tubular epithelial cells [38] might regulate the tubular
cell function. Recent reports showed that the TGF-/3 affects
tubular function or tubular hypertrophy [5, 6]. We observed that
the renal tubular cells have type II TGF-J3 receptor mRNA by
RT-PCR (unpublished data), in which the cytoplasmic portion has
a serine/threonine kinase domain that is important for the signal
transduction [41, 42]. Thus it is possible that the small TGF-13
complex from tubular epithelial cells, which may be in a secretory
form, may control tubular function in an autocrine or paracrine
mechanisms.
Our previous study of a progressive renal deterioration model
showed a discrepancy between the LTBP message and the
TGF-131 message in the diseased kidney, and the LTBP message
level correlated with ECM synthesis [2]. Our recent experiments
showed that the in situ TGF-f31 message predominantly increased
in tubular cells at the early stages in which the renal tissues were
fairly intact, while the immunostaining of LTBP was only slight.
However, the increased expression of TGF-f3 message and the
increased immunostaining of LTBP was observed in the inter-
stitial area at the late stages in which interstitial fibrosis devel-
oped. These results suggest that the small latent TGF-/3 may be
secreted at the early stages, while the large latent TGF-p may be
secreted at the late stages. The secretion of the small latent
TGF-J3 by tubular cells may be an early biological response to the
initial cell damage. In contrast, the large latent TGF-/3 may
contribute the ECM metabolism in fibrotic changes of interstitium
at the late stages. The discrepancy may be partly explained by the
different component of LTBP and/or TGF-f3 producing renal
resident cells, as shown in the present study. But the infiltrating
cells also might be a source of the large latent TGF-13 in this
model. We postulate that LTBP plays a crucial role in progression
of renal interstitial fibrosis and sclerosis. Further studies on the
pathophysiology of LTBP in diseased kidney using in situ hybrid-
ization and immunohistochemistry are ongoing.
In summary, the main finding of our study is that every nephron
segment, glomerulus and the renal arteriole expresses mRNA of
TGF-131, while LTBP mRNA is only expressed in the glomerulus
and renal arteriole of the normal rat. These results suggest that
TGF-131 is an important factor for structural and functional
homeostasis in the nephron, and that tubular epithelial cells and
glomerular cells secrete the small latent TGF-131 and the large
latent TGF-/31, respectively, which have different structures and
thus potentially have different biological functions. Further stud-
ies on the physiological and pathophysiological function of small
TGF-13 complex and large TGF-/3 complex are needed.
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